Content about Pharmaceutical industry in China

August 17, 2012

Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

Ranbaxy announced the launch, through subsidiary Ranbaxy Pharmaceuticals and under an agreement with Takeda, of pioglitazone hydrochloride tablets, an authorized generic version of Takeda's Actos. An authorized generic is a branded drug marketed at a reduced price under its generic name, typically by a third-party company operating under contract with the original branded drug's manufacturer.

August 9, 2012

Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

SCHAUMBURG, Ill. — Drug maker Sagent Pharmaceuticals has launched a generic chemotherapy drug, the company said Thursday.

Sagent announced the launch of oxaliplatin, a generic version of Sanofi's Eloxatin.

Various versions of the drug had sales of about $1.7 billion during the 12-month period ended in June, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

August 6, 2012

Generic drug maker Amneal Pharmaceuticals will spend $120 million to expand three of its plants, the company said Monday.

BRIDGEWATER, N.J. — Generic drug maker Amneal Pharmaceuticals will spend $120 million to expand three of its plants, the company said Monday.

Amneal said it would spend the money over a two-year period lasting through 2014 to "significantly" grow operations at research-and-development, manufacturing and distribution plants in New York, New Jersey and Kentucky. The company, which employs more than 1,100 people in the United States, said the expansion would create 500 more jobs.

August 6, 2012

The Food and Drug Administration has approved several generic versions of a drug used to treat asthma and allergies, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved several generic versions of a drug used to treat asthma and allergies, the agency said Friday.

The FDA announced the approval of montelukast sodium, a drug indicated for controlling asthma symptoms and relieving indoor and outdoor allergies.

The drug is a generic version of Merck's Singulair, which had sales of $4.6 billion in 2011, according to IMS Health.

July 31, 2012

Abon Pharmaceuticals is challenging the patent protection on an injected drug used to treat leukemia in children and adolescents, the company said Tuesday.

NORTHVALE, N.J. — Abon Pharmaceuticals is challenging the patent protection on an injected drug used to treat leukemia in children and adolescents, the company said Tuesday.

Abon said it filed with the Food and Drug Administration for regulatory approval of clofarabine in the 1 mg-per-mL strength. The drug is a generic version of Genzyme's Clolar, used to treat relapsed or refractory acute lymphoblastic leukemia in patients ages one to 21 years, who already have undergone at least two regimens.

July 31, 2012

AmerisourceBergen on Tuesday announced that it has signed a three-year agreement to supply approximately $18.5 billion in pharmaceuticals to Express Scripts on an annual basis.

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday announced that it has signed a three-year agreement to supply approximately $18.5 billion in pharmaceuticals to Express Scripts on an annual basis. The agreement is effective Oct. 1.

“We are honored that Express Scripts has chosen AmerisourceBergen to supply the brand pharmaceuticals it needs for its recently combined mail-order and specialty pharmacy business,” said Steven Collis, AmerisourceBergen president and CEO.

July 30, 2012

Generic drug maker Watson Pharmaceuticals is challenging the patent protection on a drug for acne and a drug for bronchospasm, the company said Monday.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals is challenging the patent protection on a drug for acne and a drug for bronchospasm, the company said Monday.

July 26, 2012

The Senate Committee on Commerce, Science and Transportation on Wednesday released a staff report on the investigation into the gray market for pharmaceuticals — what the committee defined as "shady operators who make enormous profits by buying hard-to-find drugs and reselling them at huge markups" — specifically naming pharmacies as a primary culprit.

WASHINGTON — The Senate Committee on Commerce, Science and Transportation on Wednesday released a staff report on the investigation into the gray market for pharmaceuticals — what the committee defined as "shady operators who make enormous profits by buying hard-to-find drugs and reselling them at huge markups" — specifically naming pharmacies as a primary culprit.

July 23, 2012

Blu Pharmaceuticals has named Joe Dombrowski to the newly created position of VP corporate development, the company said.

FRANKLIN, Ky. — Blu Pharmaceuticals has named Joe Dombrowski to the newly created position of VP corporate development, the company said.

Blu, based in Franklin, Ky., said Dombrowski will be responsible for strategic planning and business development, including mergers and acquisitions. Blu was founded in 2006.

Dombrowski previously worked as senior director for strategic planning and business development for Kremers Urban Pharmaceuticals.

July 16, 2012

Walgreens and Alliance Boots — it’s a trans-Atlantic retail pharmacy game-changer. 


Walgreens and Alliance Boots — it’s a trans-Atlantic retail pharmacy game-changer. 


As the largest single purchaser of prescription drugs in the world, with 11,000 retail pharmacies in 12 countries that currently dispense more than 260 million prescriptions a year, and a global pharmaceutical wholesale operation to match, serving more than 180,000 healthcare outlets worldwide, the new company will have a whole lot more leverage on that side of the business. 


June 21, 2012

As much as CVS created a category of one for itself with its vertically integrated retail pharmacy-pharmacy benefit manager-clinic model, Walgreens has cast itself in a category of its own: A pharmacy-driven, global health-and-wellness company with the purchasing strength of more than 11,000 stores.

WHAT IT MEANS AND WHY IT'S IMPORTANT — As much as CVS created a category of one for itself with its vertically integrated retail pharmacy-pharmacy benefit manager-clinic model, Walgreens has cast itself in a category of its own: A pharmacy-driven, global health-and-wellness company with the purchasing strength of more than 11,000 stores.

(THE NEWS: Walgreens, Alliance Boots to merge. For the full story, click here)

May 29, 2012

Generic drug maker Watson Pharmaceuticals has entered a settlement that will allow it to launch a generic patch used to treat post herpetic neuralgia, a pain disorder associated with shingles.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has entered a settlement that will allow it to launch a generic patch used to treat post herpetic neuralgia, a pain disorder associated with shingles.

Watson announced Tuesday a settlement through one of its subsidiaries with Endo Pharmaceuticals and Teikoku Seiyaku Co. over its generic version of Lidoderm (lidocaine) topical patch. Lidoderm had sales of $1.2 billion during the 12-month period ended in March 2012, according to IMS Health.

May 24, 2012

The parent company of Endo Pharmaceuticals has changed its name, the company said.

CHADDS FORD, Pa. — The parent company of Endo Pharmaceuticals has changed its name, the company said.

Shareholders of Endo Pharmaceutical Holdings voted at the company's annual shareholder meeting Wednesday to change the company's name to Endo Health Solutions. The company said the name change would more accurately reflect its new business model, which aggregates four operating businesses into one enterprise.

May 17, 2012

Sagent Pharmaceuticals has launched a generic version of a chemotherapy drug, the company said Thursday.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a generic version of a chemotherapy drug, the company said Thursday.

Sagent announced the launch of irinotecan injection, a generic version of Pfizer's Camptosar, in latex-free, preservative-free, single-dose vials.

Various versions of the drug had sales of about $28 million during the 12-month period ended in March, according to IMS Health.

May 16, 2012

CVS Caremark has aggressively set its sights on enhancing medication adherence, and the initiatives are paying off as the company estimates that its PBM clients saved nearly $2.4 billion in 2011 because of improved medication adherence for chronic conditions, according to findings of its annual Insights Report.

WOONSOCKET, R.I. — CVS Caremark has aggressively set its sights on enhancing medication adherence, and the initiatives are paying off as the company estimates that its PBM clients saved nearly $2.4 billion in 2011 because of improved medication adherence for chronic conditions, according to findings of its annual Insights Report.

The report, released on Wednesday, reviews drug trend and highlights key issues in pharmacy care. 

May 10, 2012

Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

Watson announced the formation of the global integration management office, which will report directly to president and CEO Paul Bisaro and focus on integrating the Zug, Switzerland-based generic drug maker, which Watson announced it would acquire last month.

April 18, 2012

Valeant Pharmaceuticals International is acquiring "certain assets" of a drug maker based in Mexico.

MONTREAL — Valeant Pharmaceuticals International is acquiring "certain assets" of a drug maker based in Mexico.

Valeant said Wednesday that it would buy gastric, analgesic and anti-inflammatory drugs from branded generics manufacturer Atlantis Pharma for $71 million. The products had sales of $26 million last year.

April 4, 2012

A court has ruled that patents covering a drug used for overactive bladder are invalid, a company looking to launch a generic version of the drug said.

PARSIPPANY, N.J. — A court has ruled that patents covering a drug designed to treat an overactive bladder are invalid, a company looking to launch a generic version of the drug said.

Watson Pharmaceuticals said the U.S. District Court for the District of Delaware ruled that five patents covering Allergan's Sanctura XR (trospium chloride) extended-release capsules were invalid. Watson's application with the Food and Drug Administration for a generic version are pending, the company said.

March 28, 2012

It’s common knowledge that pharmaceuticals have provided humankind with almost miraculous benefits over the past century in their ability to prevent, cure or reduce the impact of disease and to prolong life. But serious errors in the way medicines are dispensed by pharmacies and self-administered by patients are taking a big and growing toll on patients’ well-being.

It’s common knowledge that pharmaceuticals have provided humankind with almost miraculous benefits over the past century in their ability to prevent, cure or reduce the impact of disease and to prolong life. But serious errors in the way medicines are dispensed by pharmacies and self-administered by patients are taking a big and growing toll on patients’ well-being.

March 26, 2012

The recent Food and Drug Administration public meeting on driving future switch potential by way of the pharmacist and/or health technology sparked some discussion on what’s next.


The recent Food and Drug Administration public meeting on driving future switch potential by way of the pharmacist and/or health technology sparked some discussion on what’s next.


March 19, 2012

Watson Pharmaceuticals is challenging the patent protection on a drug made by Abbott for treating cholesterol, the company said.

PARSIPPANY, N.J. — Watson Pharmaceuticals is challenging the patent protection on a drug made by Abbott for treating cholesterol, the company said.

Watson, through a subsidiary, filed with the Food and Drug Administration for approval of niacin extended-release tablets in the 500-mg and 1,000-mg strengths. The drug is a generic version of Abbott's Niaspan.

March 14, 2012

Endo Pharmaceuticals is hoping the Food and Drug Administration will back tougher regulatory approval requirements for generic versions of one of its drugs.

CHADDS FORD, Pa. — Endo Pharmaceuticals is hoping the Food and Drug Administration will back tougher regulatory approval requirements for generic versions of one of its drugs.

February 27, 2012

The Food and Drug Administration turned down an application for a topical reproductive drug made by Watson Pharmaceuticals and Columbia Labs, the two companies said Monday.

PARSIPPANY, N.J. — The Food and Drug Administration turned down an application for a topical reproductive drug made by Watson Pharmaceuticals and Columbia Labs, the two companies said Monday.

February 22, 2012

Novartis plans to pay up to $440 million for rights to a drug for treating hepatitis C made by Enanta Pharmaceuticals, Enanta said.

WATERTOWN, Mass. — Novartis plans to pay up to $440 million for rights to a drug for treating hepatitis C made by Enanta Pharmaceuticals, Enanta said.

Enanta said it had made a licensing agreement with the Swiss drug maker for the worldwide development, manufacturing and commercialization of the drug EDP-239, which works by inhibiting NS5A, a protein that is key to the virus' replication.

February 13, 2012

Columbia Labs has transferred a new drug application for a topical drug designed to prevent premature birth in pregnant women to Watson Pharmaceuticals.

LIVINGSTON, N.J. and PARSIPPANY, N.J. — Columbia Labs has transferred a new drug application for a topical drug designed to prevent premature birth in pregnant women to Watson Pharmaceuticals.

Columbia Labs said Watson now has full rights and regulatory responsibility for all activities and sponsor obligations relating to the application for progesterone vaginal gel 8%. Late last month, the drug received a thumbs-down from an FDA panel that declined to recommend approval for it.

The FDA is expected to take action on the NDA by Feb. 26.